Metformin is the most widely prescribed medication for type 2 diabetes, and its primary purpose is to lower blood sugar by reducing the amount of glucose your liver produces. It typically reduces HbA1c (a measure of average blood sugar over three months) by about 1.1 percentage points when used alone, which is enough to bring many people from poorly controlled diabetes into a healthier range. But metformin’s story extends well beyond blood sugar, which is why so many people without diabetes take it too.
How Metformin Lowers Blood Sugar
Your liver constantly releases glucose into your bloodstream, even between meals. In type 2 diabetes, this process ramps up and becomes a major driver of high blood sugar. Metformin works primarily by dialing back that overproduction.
At the cellular level, metformin blocks a specific enzyme involved in converting certain raw materials (glycerol and lactate) into new glucose molecules. This disrupts the liver’s glucose-manufacturing pathway. For years, researchers believed metformin worked mainly by activating an energy-sensing molecule called AMPK, but more recent evidence from the Endocrine Reviews suggests that this activation only occurs at drug concentrations far higher than what patients actually have in their blood. The real action, at normal doses, appears to be this more targeted enzyme inhibition.
Metformin does not cause your body to produce more insulin, which is an important distinction. Because it doesn’t push insulin levels up, it carries virtually no risk of hypoglycemia (dangerously low blood sugar) when used on its own. This safety advantage is a major reason it remains the first-line treatment for type 2 diabetes decades after its introduction.
What to Expect When You Start
Metformin isn’t instant. The drug reaches steady levels in your blood within about two weeks, and measurable improvements in fasting blood sugar typically show up by week four. Full effects on HbA1c take around three months to assess, since that marker reflects a rolling average. Most people start on a lower dose that gets gradually increased over a few weeks, which helps reduce the gastrointestinal side effects (nausea, diarrhea, stomach cramps) that are common early on. These side effects usually fade as your body adjusts. An extended-release version of the drug causes fewer stomach issues for many people.
Use in Polycystic Ovary Syndrome
Metformin is frequently prescribed off-label for polycystic ovary syndrome (PCOS), a hormonal condition closely linked to insulin resistance. In women with PCOS, metformin improves insulin sensitivity, lowers testosterone levels, and can shorten menstrual cycles by roughly 38 days compared to placebo, helping restore more regular periods. In adolescents with PCOS, metformin was 2.5 times more likely to restore menstrual cycles compared to placebo.
The benefits appear in both normal-weight and overweight women, though the specific improvements differ. Normal-weight women see more pronounced reductions in androgen hormones, while overweight women tend to see clearer improvements in fasting glucose. Metformin alone doesn’t reliably reduce excess hair growth, and combining it with lifestyle changes like exercise and dietary improvements tends to produce better overall results than either approach alone.
Effects on Weight
Metformin causes modest weight loss in most people who take it, though the amount varies widely depending on the context. In the landmark Diabetes Prevention Program trial, participants lost an average of 2.1 kg (about 4.6 pounds) over nearly three years, and that loss held steady over long-term follow-up. In studies of people with obesity but no diabetes, losses averaged around 5.8 kg (about 12.8 pounds), though with significant variation between individuals. People taking antipsychotic medications, which commonly cause weight gain, lost an average of 3.3 kg on metformin.
These numbers are modest compared to newer weight-loss medications, but metformin is far cheaper, has a longer safety track record, and is sometimes used as a starting point or complement to other approaches.
Interest in Aging and Longevity
Beyond its established uses, metformin has attracted serious scientific interest as a potential tool for slowing biological aging. Animal studies and lab research suggest it influences several processes tied to age-related decline: chronic inflammation, cellular damage from oxidative stress, the buildup of senescent (“zombie”) cells that no longer function properly, and the body’s ability to clear out damaged cellular components.
Researchers at the Albert Einstein College of Medicine have been studying whether metformin can shift gene activity in muscle and fat tissue toward a younger profile. The hypothesis is straightforward: if metformin changes the underlying biology of aging, it could potentially delay or prevent multiple age-related diseases at once rather than treating them one by one. This research is still in relatively early stages, and metformin is not approved or recommended as an anti-aging drug.
Kidney Function and Safety Limits
Metformin is cleared from the body through the kidneys, which means kidney function determines whether the drug is safe to use. Current American Diabetes Association guidelines set clear thresholds based on estimated kidney filtration rate (eGFR). If your eGFR falls below 45, your doctor should reassess whether continuing metformin makes sense. It should not be started in anyone with an eGFR below 45, and it is fully contraindicated below 30. People with moderately reduced kidney function (eGFR 30 to 60) also need to temporarily stop metformin before receiving contrast dye for certain imaging procedures.
The concern behind these limits is lactic acidosis, a rare but serious condition where lactic acid builds up in the blood. In practice, this occurs in fewer than 10 cases per 100,000 patient-years, making it genuinely uncommon. Nearly all reported cases involve other contributing factors like severe kidney impairment, liver disease, or acute illness. For people with normal kidney function, the risk is negligible.
Vitamin B12 and Long-Term Use
About 17.5% of long-term metformin users develop vitamin B12 deficiency. This can creep up slowly over years and cause symptoms that mimic diabetic nerve damage: tingling, numbness, and weakness in the hands and feet. Because the symptoms overlap, B12 deficiency in metformin users sometimes goes unrecognized. Periodic blood testing for B12 levels is worthwhile if you’ve been on metformin for several years, and supplementation corrects the problem easily when it’s caught.